Press releases
- NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
- NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
- NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
- NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
- NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
- NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
- NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
- NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
- NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
More ▼
Key statistics
On Friday, NovaBay Pharmaceuticals Inc (B9P0:BER) closed at 1.76, 0.00% above its 52-week low of 1.76, set on Jul 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.76 |
---|---|
High | 1.76 |
Low | 1.76 |
Bid | 0.635 |
Offer | 0.667 |
Previous close | 1.95 |
Average volume | 2.90k |
---|---|
Shares outstanding | 1.35m |
Free float | 1.35m |
P/E (TTM) | -- |
Market cap | 944.10k USD |
EPS (TTM) | -108.80 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:08 BST.
More ▼